SB17170 Phase 2 Trial in IPF Patients

A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.

SB17170 Phase 2 Trial in IPF Patients (NCT06747923) is a Phase 2 interventional studying IPF and Idiopathic Pulmonary Fibrosis, sponsored by SPARK Biopharma. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against IPF and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

With a target enrollment of 30 participants, this is a small study — typical of early-phase research, rare-disease trials, or pilot studies designed to generate preliminary signal before a larger study is launched.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Adult male/female 40 years or older at the time of obtaining willing to sign a consent form 2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria: - Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan - Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit 3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria 4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit 5. Patients meeting pulmonary function test criteria at the screening visit 6. Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the willing to sign a consent form form Who Should NOT Join This Trial: 1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities 2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period 3. Patients with lower respiratory tract infections requiring antibiotic treatment 4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial 5. Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening 6. Patients with evidence of active infection 7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening: - Severe hypertension within 3 months - Myocardial infarction or unstable angina within 6 months - History of thrombotic events within 6 months ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Adult male/female 40 years or older at the time of obtaining informed consent 2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria: * Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan * Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit 3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria 4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit 5. Patients meeting pulmonary function test criteria at the screening visit 6. Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form Exclusion Criteria: 1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities 2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period 3. Patients with lower respiratory tract infections requiring antibiotic treatment 4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial 5. Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening 6. Patients with evidence of active infection 7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening: * Severe hypertension within 3 months * Myocardial infarction or unstable angina within 6 months * History of thrombotic events within 6 months * Diagnosis of heart failure within 6 months 8. Patients with pulmonary hypertension 9. Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product 10. Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C

Treatments Being Tested

DRUG

SB17170

Taking SB17170 orally once a day

DRUG

Placebo

Taking Placebo orally once a day

Locations (5)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

Myong Ji Hospital

Goyang, South Korea

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, South Korea

Seoul Asan Hospital

Seoul, South Korea

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul, South Korea

Ajou University Hospital

Suwon, South Korea

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06747923), the sponsor (SPARK Biopharma), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06747923 clinical trial studying?

Who can participate in NCT06747923?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06747923?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06747923. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06747923. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.